R G Holloway

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi A systematic review of cost-effectiveness research of stroke evaluation and treatment
    R G Holloway
    Department of Neurology, University of Rochester School of Medicine, Rochester, NY, USA
    Stroke 30:1340-9. 1999
  2. ncbi Clinical trial end points: on the road to nowhere?
    Robert G Holloway
    Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14620, USA
    Neurology 58:679-86. 2002
  3. ncbi Development of performance measures for acute ischemic stroke
    R G Holloway
    Department of Neurology, University of Rochester School of Medicine, NY, USA
    Stroke 32:2058-74. 2001
  4. ncbi Quantitative risk-benefit analysis of natalizumab
    J P Thompson
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 71:357-64. 2008
  5. ncbi Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study
    K Noyes
    Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14620, USA
    Neurology 77:355-63. 2011
  6. ncbi Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
    Neurology 68:384-6. 2007
  7. ncbi Invited Article: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines
    R G Holloway
    Department of Neurology, University of Rochester, 601 Elmwood Avenue, Box 673, Rochester, NY 14642, USA
    Neurology 71:57-63. 2008
  8. ncbi Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis
    K J Tomaszewski
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA
    Neurology 57:663-71. 2001
  9. ncbi Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Neurology 68:1524-8. 2007
  10. ncbi Selegiline shortage: Causes and costs of a generic drug shortage
    E R Dorsey
    Department of Neurology, University at Buffalo, NY, USA
    Neurology 73:213-7. 2009

Detail Information

Publications43

  1. ncbi A systematic review of cost-effectiveness research of stroke evaluation and treatment
    R G Holloway
    Department of Neurology, University of Rochester School of Medicine, Rochester, NY, USA
    Stroke 30:1340-9. 1999
    ..This work was undertaken to review research addressing the cost-effectiveness of stroke-related diagnostic, preventive, or therapeutic interventions...
  2. ncbi Clinical trial end points: on the road to nowhere?
    Robert G Holloway
    Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14620, USA
    Neurology 58:679-86. 2002
    ....
  3. ncbi Development of performance measures for acute ischemic stroke
    R G Holloway
    Department of Neurology, University of Rochester School of Medicine, NY, USA
    Stroke 32:2058-74. 2001
    ..The purpose of the present study was to develop and rate performance measures for hospital-based acute ischemic stroke...
  4. ncbi Quantitative risk-benefit analysis of natalizumab
    J P Thompson
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 71:357-64. 2008
    ..To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS)...
  5. ncbi Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study
    K Noyes
    Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14620, USA
    Neurology 77:355-63. 2011
    ..To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients with relapsing multiple sclerosis (MS)...
  6. ncbi Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
    Neurology 68:384-6. 2007
    ..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030...
  7. ncbi Invited Article: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines
    R G Holloway
    Department of Neurology, University of Rochester, 601 Elmwood Avenue, Box 673, Rochester, NY 14642, USA
    Neurology 71:57-63. 2008
    ..Clinical practice guidelines (CPGs) shape clinical care worldwide but are prone to potential error and bias due to conflicts of interest (COI)...
  8. ncbi Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis
    K J Tomaszewski
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA
    Neurology 57:663-71. 2001
    ..In treating PD, deep brain stimulation (DBS) has shown great promise in a series of uncontrolled studies...
  9. ncbi Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Neurology 68:1524-8. 2007
    ..033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days)...
  10. ncbi Selegiline shortage: Causes and costs of a generic drug shortage
    E R Dorsey
    Department of Neurology, University at Buffalo, NY, USA
    Neurology 73:213-7. 2009
    ..We sought to evaluate prescription trends of generic selegiline and to quantify the economic impact of any resulting drug substitution of more expensive alternatives...
  11. ncbi Initial treatment of early Parkinson's disease: a review of recent, randomized controlled trials
    K Biglan
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Curr Neurol Neurosci Rep 1:329-36. 2001
    ....
  12. ncbi Employment-seeking experiences of residents in 1996: a window into the neurology marketplace
    W L Larson
    Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
    Neurology 54:214-8. 2000
    ..To assess career choice and employment-seeking experience of senior neurology residents in 1996...
  13. ncbi Neurologists' use of ICD-9CM codes for dementia
    M Pippenger
    Department of Neurology, University of California, Los Angeles, 90095 1769, USA
    Neurology 56:1206-9. 2001
    ..Other codes used were not inaccurate but would result in lower reimbursement. Variation in coding could affect validity of dementia research using claims data...
  14. ncbi Health care costs decline after successful epilepsy surgery
    J T Langfitt
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Neurology 68:1290-8. 2007
    ..There is little information about how health care costs are affected by evaluation and surgery...
  15. ncbi Invited article: Neurology and quality improvement: an introduction
    C T Bever
    Department of Neurology, University of Maryland Hospital, Room N4W46, 22 South Greene Street, Baltimore, MD 21201, USA
    Neurology 70:1636-40. 2008
  16. ncbi Financial anatomy of neuroscience research
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Ann Neurol 60:652-9. 2006
    ..To estimate the level of funding for neuroscience research from federal and industry sources and to examine the therapeutic advances in the neurosciences over the past decade...
  17. ncbi The safety of hospital stroke care
    Robert G Holloway
    Office of Clinical Practice Evaluation, Strong Memorial Hospital, NY, USA
    Neurology 68:550-5. 2007
    ..To analyze medical errors and adverse events occurring in stroke patients and to provide insights into system or stroke-specific processes that can be modified to reduce the likelihood of error and patient harm...
  18. ncbi Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients
    Sally A Norton
    School of Nursing, University of Rochester Medical Center, Rochester, NY, USA
    Crit Care Med 35:1530-5. 2007
    ..The purpose of this study was to examine the effect of proactive palliative care consultation on length of stay for high-risk patients in the medical intensive care unit (MICU)...
  19. ncbi Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
    Kevin M Biglan
    University of Rochester, Department of Neurology, Rochester, NY 14620, USA
    Neurology 69:187-95. 2007
    ..A secondary finding of the trial was a higher than anticipated development or worsening of somnolence and edema and development of hallucinations...
  20. ncbi A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia
    Alec B O'Connor
    Department of Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA
    J Am Geriatr Soc 55:1176-84. 2007
    ..To compare the net health effects and costs resulting from treatment with different first-line postherpetic neuralgia (PHN) medications...
  21. ncbi Mortality as a measure of quality: implications for palliative and end-of-life care
    Robert G Holloway
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    JAMA 298:802-4. 2007
  22. ncbi The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation
    Katia Noyes
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York 14620, USA
    Med Decis Making 27:327-34. 2007
    ..The objective of this study is to examine the effect of country-specific EQ-5D preference weights on the cost-effectiveness (CE) of initial pramipexole versus levodopa strategy in patients with Parkinson disease (PD)...
  23. ncbi Biomarkers in Parkinson's disease
    E Ray Dorsey
    University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 223, Rochester, NY 14620, USA
    Expert Rev Neurother 6:823-31. 2006
    ..However, to date, biomarkers, despite their considerable promise, have had limited utility in clinical trials and practice...
  24. ncbi What is the risk of developing parkinsonism following neuroleptic use?
    Katia Noyes
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, NY, USA
    Neurology 66:941-3. 2006
    ..Although more research is needed, these data suggest that 126 Medicare beneficiaries would need to be treated with neuroleptic medications to cause one additional case of self-reported PD...
  25. ncbi Surrogate endpoints in Parkinson's disease research
    Kevin M Biglan
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Rochester, NY 14620, USA
    Curr Neurol Neurosci Rep 3:314-20. 2003
    ..Finally, the significant challenges that lie ahead for validating and interpreting surrogate endpoints in PD are addressed...
  26. ncbi Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysis
    Scott Y H Kim
    Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Am J Psychiatry 160:1272-6. 2003
    ..The authors assessed the cost-effectiveness of entering such a trial from the perspective of potential subjects...
  27. ncbi Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  28. ncbi Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial
    Katia Noyes
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, USA
    Med Decis Making 24:472-85. 2004
    ..If initial pramipexole results in long-term improvements in quality of life, its cost-effectiveness will become more favorable...
  29. ncbi CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes
    Ronald H Gottlieb
    Dept of Radiology, Univ of Rochester Medical Ctr, NY 14642, USA
    Radiology 225:441-9. 2002
    ....
  30. ncbi Evidence from cost-effectiveness research
    Katia Noyes
    Department of Community and Preventive Medicine, University of Rochester, NY 14620, USA
    NeuroRx 1:348-55. 2004
    ....
  31. ncbi Responsiveness of life-threatening refractory emesis to gabapentin-scopolamine therapy following posterior fossa surgery. Case report
    Thomas Guttuso
    Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14214, USA
    J Neurosurg 102:547-9. 2005
    ....
  32. ncbi How much is a good night's sleep worth?
    Linda S Williams
    Stroke 36:1293-4. 2005
  33. ncbi Prognosis and decision making in severe stroke
    Robert G Holloway
    Department of Neurology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    JAMA 294:725-33. 2005
    ..An increasing number of deaths following severe stroke are due to terminal extubations. Variation in withdrawal-of-care practices suggests the possibility of unnecessary prolongation of suffering or of unwanted deaths...
  34. ncbi A review of pramipexole and its clinical utility in Parkinson's disease
    Kevin M Biglan
    University of Rochester, Department of Neurology, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Expert Opin Pharmacother 3:197-210. 2002
    ..In addition to its use in PD, pramipexole has shown some utility in the treatment of restless legs syndrome (RLS), depression and schizophrenia...
  35. ncbi Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness
    Katia Noyes
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York 14620, USA
    Pharmacoeconomics 23:1257-70. 2005
    ..In this article we analyse the dynamic changes in cumulative costs, effects and incremental cost effectiveness of two competing drug strategies in patients with early Parkinson's disease (PD)...
  36. ncbi Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life
    Katia Noyes
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, NY 14620, USA
    Value Health 9:28-38. 2006
    ..Here we assess the effect of therapy on HRQOL and explore factors that influence the HRQOL profiles and subdomains...
  37. ncbi Development and testing of the Parkinson's disease quality of life scale
    Mickie Welsh
    Department of Neurology, University of Southern California, Los Angeles, California, USA
    Mov Disord 18:637-45. 2003
    ..Continuing development of the PDQUALIF will be directed at enhancing the psychometric properties, establishing responsiveness and determining appropriateness in culturally diverse samples...
  38. ncbi Update in neurology
    Robert G Holloway
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Ann Intern Med 144:421-6. 2006
  39. ncbi Quality of life in epilepsy, multiple sclerosis, and beyond
    E Ray Dorsey
    Ann Neurol 62:307-8. 2007
  40. ncbi Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations
    Christopher G Goetz
    Rush University Medical Center, 1725 W Harrison Street, Chicago, IL 60612, USA
    Mov Disord 19:1020-8. 2004
    ..5 increments, this adaptation warrants clinimetric testing. Without such testing, however, the original five-point scales should be maintained...
  41. ncbi Evidence-based neurotherapeutics: a spectrum of evidence
    Robert G Holloway
    NeuroRx 1:295-7. 2004
  42. ncbi Diffusion tensor imaging: scientific advance, clinical tool, or just a pretty picture?
    Deborah M Little
    Neurology 68:9-10. 2007
  43. ncbi Ethics of sham surgery: perspective of patients
    Samuel A Frank
    Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA
    Mov Disord 23:63-8. 2008
    ..Future research needs to determine whether eliciting more considered judgments of laypersons would reveal different levels of support for sham surgery...